Advisory Research’s Treace Medical Concepts TMCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-12,056
Closed -$308K 489
2023
Q2
$308K Buy
12,056
+1,272
+12% +$32.8K 0.04% 371
2023
Q1
$272K Sell
10,784
-36,060
-77% -$847K 0.04% 302
2022
Q4
$1.08M Sell
46,844
-65,501
-58% -$1.51M 0.1% 153
2022
Q3
$2.48M Buy
+112,345
New +$2.17M 0.24% 76

Other funds holding TMCI

Advisory Research's TMCI Position: Q3 2023 in Review

Advisory Research sold out of Treace Medical Concepts (TMCI) in Q3 2023, closing a stake of 12,056 shares — an estimated $308K sold.

Advisory Research first reported a position in TMCI in Q3 2022 and held it in 4 quarters. The position peaked at $2.48M in Q3 2022. 123 funds tracked by Wall St. Rank hold TMCI as of Q3 2023.

  • Advisory Research reported no remaining Treace Medical Concepts position as of Q3 2023 after selling out during the quarter.
  • Advisory Research sold 12,056 Treace Medical Concepts shares in Q3 2023, an estimated $308K.
  • Advisory Research first reported a position in Treace Medical Concepts in Q3 2022 and held it in 4 quarters.
  • Advisory Research's Treace Medical Concepts position peaked at $2.48M in Q3 2022.
  • 123 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q3 2023.

Based on Advisory Research's 13F filing for Q3 2023, filed 13 Nov 2023.